Amplicon deep sequencing improves Plasmodium falciparum genotyping in clinical trials of antimalarial drugs

• Published in: Scientific reports Vol. 9; no. 1; pp. 17790 - 12
• Main Authors: Gruenberg, Maria, Lerch, Anita, Beck, Hans-Peter, Felger, Ingrid
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 28.11.2019; Nature Publishing Group
• Subjects: 45; 45/23; 45/77; 692/308/174; 692/308/409; 692/699/255/1629; Antimalarials - therapeutic use; Clinical trials; Discordance; DNA, Protozoan - genetics; Drug resistance; Drug Resistance - genetics; Genotype; Genotyping; Genotyping Techniques; Haplotypes; High-Throughput Nucleotide Sequencing - methods; Humanities and Social Sciences; Humans; Malaria; Malaria, Falciparum - drug therapy; Malaria, Falciparum - virology; multidisciplinary; Parasites; Patients; Plasmodium falciparum; Plasmodium falciparum - genetics; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Recurrent infection; Reproducibility of Results; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-019-54203-0

Clinical trials monitoring malaria drug resistance require genotyping of recurrent Plasmodium falciparum parasites to distinguish between treatment failure and new infection occurring during the trial follow up period. Because trial participants usually harbour multi-clonal P. falciparum infections, deep amplicon sequencing (AmpSeq) was employed to improve sensitivity and reliability of minority clone detection. Paired samples from 32 drug trial participants were Illumina deep-sequenced for five molecular markers. Reads were analysed by custom-made software HaplotypR and trial outcomes compared to results from the previous standard genotyping method based on length-polymorphic markers. Diversity of AmpSeq markers in pre-treatment samples was comparable or higher than length-polymorphic markers. AmpSeq was highly reproducible with consistent quantification of co-infecting parasite clones within a host. Outcomes of the three best-performing markers, cpmp, cpp and ama1-D3 , agreed in 26/32 (81%) of patients. Discordance between the three markers performed per sample was much lower by AmpSeq (six patients) compared to length-polymorphic markers (eleven patients). Using AmpSeq for discrimination of recrudescence and new infection in antimalarial drug trials provides highly reproducible and robust characterization of clone dynamics during trial follow-up. AmpSeq overcomes limitations inherent to length-polymorphic markers. Regulatory clinical trials of antimalarial drugs will greatly benefit from this unbiased typing method.